vimarsana.com

Latest Breaking News On - Aperion biologics - Page 1 : vimarsana.com

Global Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Global Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Berkeley
California
United-states
United-kingdom
Texas
Singapore
Austria
Dublin
Ireland
Canada
Blue-sky
Alberta

Global Cancer Monoclonal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Global Cancer Monoclonal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Dublin
Ireland
Texas
United-states
Ascentage-pharma
Atlab-pharma
Aeglea-biotherapeutics
Calithera-biosciences
Aperion-biologics
Bio-farma
Aytu-bioscience

Global Cancer Monoclonal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021

Global Cancer Monoclonal Antibody Partnering Deals Report/Directory 2021: Trends, Players and Financials 2014-2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Dublin
Ireland
Texas
United-states
Ascentage-pharma
Atlab-pharma
Aeglea-biotherapeutics
Calithera-biosciences
Aperion-biologics
Bio-farma
Aytu-bioscience

Investegate |Tissue Regenix Group Announcements | Tissue Regenix Group: Appointment of Chief Financial Officer

About Tissue Regenix ( www.tissueregenix.com ) Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company s patented decellularisation ( dCELL® ) technology removes DNA and other cellular material from animal and human soft tissue leaving an acellular tissue scaffold which is not rejected by the patient s body and can then be used to repair diseased or worn out body parts. Current applications address many critical clinical needs such as sports medicine, heart valve replacement and wound care. In August 2017 Tissue Regenix acquired CellRight Technologies®, a biotech company that specializes in regenerative medicine and is dedicated to the development of innovative osteoinductive and wound care scaffolds that enhance healing opportunities of defects created by trauma and disease. CellRight s human osteobiologics may be used in spine, trauma, general orthopaedic, foot & ankle, dental, and sports medicine surgical

Ben-maddison-alex
Daniel-lee
David-claiborne-cocke
Caitlin-pearson
David-cocke
Aperion-biologics
Katena-products-inc
Head-of-communications
Stifel-nicolaus-europe-limited-nominated-adviser
Nupak-medical-ltd
Walbrook-pr-ltd
Tissue-regenix-group

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.